KPS
Functional Service Provider
The Multidisciplinary Association for Psychedelic Studies (MAPS) is producing the first-in-class innovator drug midomafetamine (MDMA) as therapy for chronic and delayed-onset post-traumatic stress disorder (PTSD), currently in Phase III development in the US and Europe. Following positive Phase II trial data confirming that midoafetamine resulted in a significant reduction in PTSD symptoms, the FDA granted it a Breakthrough Therapy Designation in 2017.
Further results proceed to prove MDMA’s effectiveness in treating PTSD. Read more here.
Functional Service Provider
Standardized Tools for Cellular Immune Assays
SaaS Platform Decentralizing Clinical Research at Scale